Ion Beam Applications, SA

Declaration of Voting Results & Voting Rights Announcements • May 5, 2014

IBA – DATA CONCERNING TRANSPARENCY

Louvain-la-Neuve, Belgium, May 5, 2014 - IBA (Ion Beam Applications SA, EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has issued today a transparency notification, in accordance with Article 29 §1 al.2 of the Transparency Law (law of May 2, 2007 and Royal Decree of February 14, 2008) and the content of which is summarized below.

Since January 20, 2014, date of the last transparency notification issued by IBA, Belgian Anchorage SCRL has sold 650 000 IBA shares with voting rights.

Sales occurred on March 28, 2014 (100 000 shares), April 15, 2014 (400 000 shares) and April 24, 2014 (150 000 shares), bringing the holding of Belgian Anchorage SCRL below the 25% threshold.

ENTITY	NUMBER OF SHARES WITH VOTING RIGHTS AS AT JANUARY 20, 2014	NUMBER OF SHARES WITH VOTING RIGHTS AS AT APRIL 24, 2014	% OF SHARES WITH VOTING RIGHTS AS AT APRIL 24, AU 2014 (DENOMINATOR = 27 667 636)
a. Belgian Anchorage SCRL (BA) Clos des Salanganes 5 1150 Bruxelles	7 560 132	6 910 132	24.98%
b. IBA SA Chemin du Cyclotron 3 1348 Louvain-la-Neuve	75 637	610 852	2.21%
c. IBA Investments SCRL Chemin du Cyclotron 3 1348 Louvain-la-Neuve	610 852	75 637	0.27%
Sub total a, b, c	8 246 621	7 596 621	27.46%

* * * *

IBA (Ion Beam Applications SA) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the

Press release | May 5, 2014 1 | 2

development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

IBA employs more than 1,000 people worldwide and is listed on Euronext Brussels, (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB), more information can be found at: www.iba-worldwide.com

For more information, please contact

IBA Jean-Marc Bothy Chief Financial Officer Tel: +32 10 47 58 90 investorrelations@iba-group.com Thomas Ralet Vice-President Corporate Communication Tel : +32 10 47 58 90 communication@iba-group.com

Press release | May 5, 2014 2 | 2